QHSLab Inc
usaqcorp.comWhat Do They Do?
Provides independent primary care practices with digital screening, clinical decision support and follow-up care, and offers allergy diagnostics and treatments for use in those practices.
10-K for FY2025, filed Mar 30, 2026QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage…View ↗
In addition to our digital health platform, we offer an allergy diagnostics and treatment service line under the AllergiEnd® brand. This…View ↗
Our digital platform (“QHSLab”) is designed to function as an extension of a medical practice’s existing clinical workflow. The platform…View ↗
How Do They Make Money?
Medical practices pay recurring per-patient fees for digital-platform access and related services; software access runs over monthly or annual agreements, and services are billed monthly. Practices also buy allergy diagnostic products and immunotherapy treatments, with sales counted when products ship.
10-K for FY2025, filed Mar 30, 2026Our revenue model consists of recurring subscription and service fees charged to participating medical practices on a per-patient…View ↗
The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians’ practices…View ↗
The Company provides administrative, billing and clinical decision support services utilizing QHSLab. Revenue is recognized each month…View ↗
The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company…View ↗
-
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by product or service ↗
$2.7M
-
10-K for FY2025, filed Mar 30, 2026
$2.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Allergy Diagnostic Kit Sales
Sold outright
10-K for FY2025, filed Mar 30, 2026 |
31% |
Allergy Diagnostic Kit Sales, FY2025
$823.1K Sources
|
Sold outright |
|
Integrated Service Program
Recurring
10-K for FY2025, filed Mar 30, 2026 |
42% |
Integrated Service Program, FY2025
$1.1M Sources
|
Recurring |
|
Immunotherapy Treatment Sales
Sold outright
10-K for FY2025, filed Mar 30, 2026 |
18% |
Immunotherapy Treatment Sales, FY2025
$487.8K Sources
|
Sold outright |
|
Clinical Study Revenue
|
5.0% |
Clinical Study Revenue, FY2025
$133.7K Sources
|
|
|
Subscription Revenue
Recurring
|
1.6% |
Subscription Revenue, FY2025
$43.7K Sources
|
Recurring |
|
Shipping and Handling
|
1.6% |
Shipping and Handling, FY2025
$41.7K Sources
|
|
|
Training and Other Revenue
|
1.5% |
Training and Other Revenue, FY2025
$40.7K Sources
|
Who Are Their Customers?
Independent, physician-led primary care practices are the target customers. QHSLab reaches them through existing relationships, referrals and targeted direct sales and marketing.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
$38KView ↗
- ▲ Now profitable
- vs −$53K in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 12, 2026
Open tableView ↗
Growing. Revenue grew 90% in 4 years, from $1.4M in FY2021 to $2.7M in FY2025, about 17% a year.
Behavioral health focus
The older report framed QHSLab broadly around chronic disease, prevention and remote monitoring; the latest centers it on screening and ongoing management of underdiagnosed behavioral health conditions in primary care.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 30, 2026We are a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCP’s) to increase…View ↗
Loading...
